A blood atlas of COVID-19 defines hallmarks of disease severity and specificity
David Ahern(University of Oxford), Susanna Dunachie(University of Oxford), David Buck(Becton Dickinson (United States)), Fabiola Curion(Helmholtz Zentrum München), Simon Davis, Tihana Bicanic(St George's, University of London), James Docker, Julie Dequaire, Andrew Brent(University of London), Alice Allcock, Sally Beer, Eleanor Barnes(Oxford Health NHS Foundation Trust), J. Kenneth Baillie(Roslin Institute), Elizabeth Clutterbuck(University of Oxford), Rachael Bashford-Rogers(University of Cambridge), Emma E. Davenport(University of Oxford), Calliope A. Dendrou(Centre for Human Genetics), Andrew Brown, Neil Davidson, Lea Dib(University of Birmingham), Christina Dold(University of Oxford), Damien J. Downes(University of Oxford), Paul Bowness(MRC Weatherall Institute of Molecular Medicine), Adam P. Cribbs(Oxford BioMedica (United Kingdom)), Hal Drakesmith, Mark Coles(University of Oxford), Chris Allan, Moustafa Attar(Centre for Human Genetics), Dominik Aschenbrenner(John Radcliffe Hospital), Sagida Bibi(University of Oxford), Amanda Y. Chong(Centre for Human Genetics), Richard J. Cornall(Centre for Human Genetics), Tao Dong(University of Oxford), Ivan Candido-Ferreira, Amy Beveridge, M. Azim Ansari(Centre for Human Genetics), Archana Bashyal, Helen M. Byrne(University of Oxford), Carolina V. Arancibia-Cárcamo, Katie L. Burnham(Centre for Human Genetics), John Broxholme(Centre for Human Genetics), Mark Ainsworth, Wentao Chen, Yi‐Ling Chen(National Taiwan University), Christopher P. Conlon(Oxford Health NHS Foundation Trust), Philip D. Charles, Luke Blackwell, G. Berridge, Susana Camara, Zhichao Ai(University of Oxford)
Cited by 35
Related Papers
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
|The Lancet|2020|2.6k
A minimal common outcome measure set for COVID-19 clinical research
|The Lancet Infectious Diseases|2020|1.8k
Global distribution and prevalence of hepatitis C virus genotypes
|Hepatology|2014|1.6k